Evidence map›Paper›PMID 27746672›Full record

ArticleMolecular vision2016

Non-toxic retention of nanoceria in murine eyes.

Xue Cai, Sudipta Seal, James F McGinnis

Abstract read
PubMed Full text at PMC
In one paragraph

Article in Molecular vision, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Article
  2. Review
  3. [Retinal protective effects of zincZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2025
    Article
  4. Article
  5. Article
  6. Pegylated nanoceria: A versatile nanomaterial for noninvasive treatment of retinal diseases.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023
    Review
  7. Review
  8. Article
  9. Article
  10. Nanotechnology for Topical Drug Delivery to the Anterior Segment of the Eye.International journal of molecular sciences · 2021
    Review
  11. Review
  12. An overview on recentAsian journal of pharmaceutical sciences · 2020
    Review
  13. Article
  14. Article
  15. Article
  16. Safety Assessment of Nanomaterials to Eyes: An Important but Neglected Issue.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2019
    Review
  17. Toxicological research · 2019
    Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Xue CaiDepartment of Ophthalmology, University of Oklahoma Health Sciences Center, Oklahoma City, OK.
Sudipta SealAdvanced Materials Processing Analysis Center, Mechanical Materials Aerospace Eng., Nanosci. and Tech. Ctr., University of Central Florida, Orlando, FL.
James F McGinnisDepartment of Ophthalmology, University of Oklahoma Health Sciences Center, Oklahoma City, OK; Department of Cell Biology, University of Oklahoma Health Sciences Center, Oklahoma City, OK; Oklahoma Neuroscience Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK.

Funding

P30-CENTER CORE GRANT FOR VISION RESEARCHP30EY021725 · NEI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI Michelle C Callegan · 2011 to 2026
$10.5M
Prolonged Inhibition of Pathologic Neovascularization by Catalytic AntioxidantsR01EY022111 · NEI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI MCGINNIS, JAMES FRANCIS · 2012 to 2015
$2.2M
Prevention of Inherited Retinal Diseases by Therapeutic Rare Earth NanoparticlesR01EY018724 · NEI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI MCGINNIS, JAMES FRANCIS · 2009 to 2010
$738k
Pharmacokinetics of Therapeutic Nanoparticles in the CNSR21EY018306 · NEI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI MCGINNIS, JAMES FRANCIS · 2007 to 2009
$555k
NEI NIH HHS P30 EY021725NEI NIH HHS R01 EY018724NEI NIH HHS R01 EY022111NEI NIH HHS R21 EY018306
6 · The paper itself

Abstract

purposeWe have shown that cerium oxide nanoparticles (nanoceria), with unique characteristics and catalytic activities, are retained in the retina for more than 1 year after a single intravitreal injection and can be potentially used for the treatment of a variety of eye diseases. The objective of this study is to determine whether the retention of nanoceria in the eye causes inflammation or adverse side effects.

methodsWild-type (C57BL/6J) mice at P30 were intravitreally injected with several concentrations of nanoceria. The health of the photoreceptors was assessed by analyzing the expression of photoreceptor-specific genes, and the retinal structure and function. The effect of nanoceria was investigated by analyzing of the vascular system, the expression of inflammatory cytokines, and cellular infiltration into the eye.

resultsOur data showed that there were no changes in the retinal structure or function, or cytokine gene expression following a single intravitreal injection of nanoceria.

conclusionsNanoceria, at doses ranging from 17.2 ng to 1720 ng per eye, do not cause any damage to the retinal structure and function by 30 days post injection. No cellular infiltration and no increases in inflammatory responses were found in the eyes. Our data indicate that nanoceria are safe to use for treatment of a variety of eye diseases.

Indexed as

AnimalsAntioxidantsBlotting, WesternCeriumElectroretinographyEye ProteinsFluorescein AngiographyImmunohistochemistryIntravitreal InjectionsMiceMice, Inbred C57BLNanoparticlesPhotoreceptor Cells, VertebrateReal-Time Polymerase Chain ReactionRetinaRNA, MessengerAntioxidantsceric oxideCeriumEye ProteinsRNA, Messenger

Identifiers

PMID27746672
PMCPMC5063092

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.